Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jul-Aug;22(5):370-3.
doi: 10.1038/sj.jp.7210748.

Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance

Ramen Chmait  1 , Patricia Franklin, Stephen A Spector, Andrew D Hull
Affiliations

Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance

Ramen Chmait et al. J Perinatol. 2002 Jul-Aug.

Abstract

Objective: To assess the impact of highly active antiretroviral therapy, including a protease inhibitor (HAART/PI), on maternal glucose tolerance and fetal growth.

Study design: A retrospective chart review of pregnancy outcomes of human immunodeficiency virus-infected pregnant women receiving HAART/PI (n=41) or zidovudine monotherapy (n=23).

Results: Abnormal 1-hour glucose tolerance tests (1hGTT) were observed in 30% of subjects receiving HAART/PI between 24 and 28 weeks' gestation. An elevated 1hGTT was associated with a significantly lower mean birth weight in subjects receiving HAART/PI compared to babies born to mothers with a normal 1hGTT (3.40+/-0.09 vs 3.00+/-0.18 kg, p<0.05, ANOVA).

Conclusion: HAART/PI therapy is associated with an increased rate of impaired glucose tolerance in pregnancy and impaired fetal growth. This finding merits further investigation.

PubMed Disclaimer